Overview
Join us for an exclusive webinar that delves into the most groundbreaking studies and updates presented at the recent American Society of Clinical Oncology (ASCO) meeting. This webinar will focus on pivotal advancements in the treatment and management of lung cancer, providing valuable insights for healthcare professionals involved in lung cancer care.
This webinar is presented by the IASLC Education Committee.
- ADRIATIC Study: Discover the latest findings on durvalumab as a consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
- Comparative Effectiveness of Early Palliative Care: Explore the comparative effectiveness trial that evaluates early palliative care delivered via telehealth versus in-person care among patients with advanced lung cancer.
- LAURA Study: Gain insights into the primary results of the phase 3 LAURA study, which investigates the use of osimertinib (OSI) after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
At the end of this webinar, participants will be able to:
- Explain durvalumab's role in LS-SCLC treatment and evaluate its impact on patient outcomes based on the ADRIATIC study.
- Analyze the benefits, challenges, and implications of integrating telehealth in palliative care.
- Evaluate the impact of targeted therapy on disease progression and survival rates.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- ADRIATIC Study: Discover the latest findings on durvalumab as a consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
- Comparative Effectiveness of Early Palliative Care: Explore the comparative effectiveness trial that evaluates early palliative care delivered via telehealth versus in-person care among patients with advanced lung cancer.
- LAURA Study: Gain insights into the primary results of the phase 3 LAURA study, which investigates the use of osimertinib (OSI) after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
At the end of this webinar, participants will be able to:
- Explain durvalumab's role in LS-SCLC treatment and evaluate its impact on patient outcomes based on the ADRIATIC study.
- Analyze the benefits, challenges, and implications of integrating telehealth in palliative care.
- Evaluate the impact of targeted therapy on disease progression and survival rates.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Rebecca S. Heist
MD
Harvard Medical School
Alissa Cooper
MD
Memorial Sloan Kettering Cancer Center
Joseph A. Greer
PhD
Harvard Medical School
Massachusetts General Cancer Center
Zosia Piotrowska
MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital